Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.

Virology journal - 31 Mar 2011

Piralla Antonio, Paolucci Stefania, Gulminetti Roberto, Comolli Giuditta, Baldanti Fausto

Abstract excerpt

BACKGROUND: HIV-1 integrase (IN) variability in treatment naïve patients with different HIV-1 subtypes is a major issue. In fact, the effect of previous exposure to antiretrovirals other than IN inhibitors (INI) on IN variability has not been satisfactorily defined. In addition, the genetic barrier for specific INI resistance mutations remains to be calculated. METHODS: IN variability was analyzed and compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV-1
Share to Drug Resistance, Viral
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Molecular Sequence Data

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 21453487
DOI: 10.1186/1743-422X-8-149
PMCID: PMC3077329

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.PMID 21453487Read ↗

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.Semantic proximity Read ↗

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitorsSemantic proximity Read ↗

Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.Semantic proximity Read ↗

Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.Semantic proximity Read ↗

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Semantic proximity Read ↗

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.Semantic proximity Read ↗

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitroSemantic proximity Read ↗

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.Semantic proximity Read ↗

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Semantic proximity Read ↗

Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil.Semantic proximity Read ↗

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Semantic proximity Read ↗

Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.